Dr. Reddy’s Laboratories Q3 Results FY25–26: Net Profit ₹1,190 Cr, Down 15.3% YoY, Revenue ₹8,727 Cr

    Synopsis:


    Dr. Reddy’s Laboratories reported consolidated revenue of ₹8,727 crore in Q3 FY25–26. Net profit for the quarter stood at ₹1,190 crore. During the quarter, profitability was impacted by higher operating expenses and R&D costs, while the company continued to strengthen its generics and biosimilars pipeline.

    Dr. Reddy’s Q3 Results FY25–26: Net Profit ₹1,190 Cr, Down 15.3% YoY, Revenue ₹8,727 Cr

    Dr. Reddy’s Laboratories Limited announced its unaudited consolidated financial results for the quarter and nine months ended 31 December 2025 (Q3 FY25–26). The results were approved by the Board of Directors at its meeting held on 21 January 2026 and disclosed to the stock exchanges.

    For the quarter, the company reported revenue of ₹8,727 crore, compared with ₹8,805 crore in Q2 FY25–26. Net profit for the period stood at ₹1,190 crore during Q3 FY25–26.

    Dr. Reddy’s Q3 Results FY25–26 – Date & Announcement

    Dr. Reddy’s Laboratories declared its Q3 FY25–26 results on 21 January 2026, following approval by the Board of Directors. Along with the financial results, the company provided updates on regulatory approvals, biosimilar filings, and strategic collaborations across key markets.

     

    Dr Reddy S Laboratories

    Trade

    1135.6-15.20 (-1.32 %)

    Updated - 28 July 2026
    1149.00day high
    DAY HIGH
    1130.20day low
    DAY LOW
    2157306
    VOLUME (BSE)

    Dr. Reddy’s Q3 Results FY25–26 – Key Financial Highlights (Consolidated)

    All figures in ₹ crore | Unaudited

    Particulars

    Q3 FY25–26

    Q2 FY25–26

    Q3 FY24–25

    QoQ %

    YoY %

    Revenue

    8,727

    8,805

    8,359

    (0.9%)

    +4.4%

    Total Operating Expenses

    3,257

    3,063

    3,033

    +6.3%

    +7.4%

    Operating Profit

    1,424

    1,751

    1,872

    (18.7%)

    (24.0%)

    Profit Before Tax (PBT)

    1,543

    1,835

    1,874

    (15.9%)

    (17.7%)

    Tax Expense

    353

    408

    470

    (13.5%)

    (24.9%)

    Net Profit (PAT)

    1,190

    1,427

    1,404

    (16.6%)

    (15.3%)

    EPS – Basic (₹)

    14.53

    17.26

    16.96

    (15.8%)

    (14.3%)

    EPS – Diluted (₹)

    14.52

    17.25

    16.94

    (15.8%)

    (14.3%)

    Dr. Reddy’s Q3 FY25–26 vs Q2 FY25–26 – Comparison (Consolidated)

    All figures in ₹ crore | Unaudited

    Particulars

    Q3 FY25–26

    Q2 FY25–26

    QoQ Change (%)

    Revenue

    8,727

    8,805

    (0.9%)

    Profit Before Tax

    1,543

    1,835

    (15.9%)

    Net Profit

    1,190

    1,427

    (16.6%)

    EPS – Basic (₹)

    14.53

    17.26

    (15.8%)

    Sequentially, revenue remained flat, while profitability declined due to higher selling expenses, increased R&D spending, and lower other income.

    Dr. Reddy’s Q3 Business Segment Performance (Consolidated)

    Segment Revenue

    All figures in ₹ crore | Unaudited

    Segment

    Q3 FY25–26

    Q2 FY25–26

    Q3 FY24–25

    Global Generics

    7,911

    7,850

    7,375

    Pharmaceutical Services & Active Ingredients

    968

    1,158

    1,022

    Others

    14

    10

    161

    Total Revenue

    8,893

    9,019

    8,559

    Less: Inter-segment Revenue

    166

    213

    200

    Net Revenue

    8,727

    8,805

    8,359

    Segment Results

    All figures in ₹ crore

    Segment

    Q3 FY25–26

    Global Generics

    4,538

    Pharmaceutical Services & Active Ingredients

    139

    Others

    5

    Total Segment Result

    4,681

    Market Reaction After Dr. Reddy’s Q3 Results FY25–26

    Dr. Reddy’s Laboratories released its quarterly results after market hours. As of 3:30 PM IST on 21 January 2026, the company’s share price was trading at ₹1,155.50 on the BSE, down 0.98% for the day.

    Conclusion – What Dr. Reddy’s Q3 Results Indicate

    Dr. Reddy’s Q3 FY25–26 results indicate stable year-on-year revenue performance supported by the Global Generics business. However, higher operating costs and continued investments in R&D impacted margins during the quarter. The company remains focused on strengthening its biosimilar pipeline and expanding its global footprint.

    For more quarterly result updates, visit Bajaj Broking’s Quarterly Results Calendar.

    Frequently Asked Questions

    Published Date : 21 Jan 2026

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    1 M+ Users

    4.8 App Rating

    4 Languages

    ₹7,300 Cr+ MTF Book

    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |